Alle Storys
Folgen
Keine Story von Dr. Hönle AG mehr verpassen.

Dr. Hönle AG

Hönle Publishes Preliminary Figures for Financial Year 2005/2006 - Net Income Increases by 9.6 %

Graefeling/Munich (euro adhoc) -

  ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for
  the content of this announcement.
The UV specialist, Dr. Hönle AG
(ISIN DE0005157101), published preliminary figures for financial year
2005/2006, reporting a 3.8 % rise to TEUR 23,693 in the Hönle Group
sales revenues in comparison with the previous year. At the same
time, earnings before interest and tax (EBIT) improved by 1.3 % to
TEUR 3,473 and earnings before tax (EBT) were with TEUR 3,997 0.9 %
under the previous year. Consolidated net income saw a 9.6 % rise and
is now TEUR 2,742. Net profit on sales came to 11.6 % (PY: 11.0 %).
The Dr. Hönle AG Supervisory Board and Board of Management will
probably propose to the General Meeting that a dividend of EUR 0.30
per share be distributed from the unappropriated retained earnings of
Dr. Hönle AG.
Liquid assets, financial assets and own shares amount to TEUR 19,085
(PY: TEUR 18,187), which corresponds to a cash proportion of EUR 3.51
per share.
Germany continued to be the most important sales market for Hönle and
accounted for 46.8 % of total sales in comparison with 47.6 % in the
previous year. At TEUR 11,081, domestic sales remained at the
previous year’s level. While sales revenues earned in the European
Union declined by 7.1 % to TEUR 7,269, sales figures outside Europe
climbed by 29.1 % to a record high of TEUR 5,343. This jump in sales
is due, in particular, to a rising demand for printing industry
plants from the North-American sales region.
Outlook: The Hönle Group extended its sales team significantly in the
last financial year and intensified its overall sales activities.
Hönle's product range was broadened as a result of the take-over of
the customer base and brand rights of Arccure Technologies GmbH, and
new customers could be gained in this context. In all, Hönle expects
the general conditions to be favourable and assumes positive
development possibilities for the corporate group. An increase in
both sales and income is expected for the new financial year.
end of announcement                               euro adhoc 23.11.2006 00:11:59

Further inquiry note:

Peter Weinert
Tel.: +49 (0)89 856 08 173
E-Mail: peter.weinert@hoenle.de

Branche: Instrument Engineering
ISIN: DE0005157101
WKN: 515710
Index: CDAX, Prime All Share, Technologie All Share
Börsen: Frankfurter Wertpapierbörse / regulated dealing/prime
standard
Börse Berlin-Bremen / free trade
Hamburger Wertpapierbörse / free trade
Baden-Württembergische Wertpapierbörse / free trade
Börse Düsseldorf / free trade
Niedersächsische Börse zu Hannover / free trade
Bayerische Börse / free trade

Weitere Storys: Dr. Hönle AG
Weitere Storys: Dr. Hönle AG